Galmed Pharmaceuticals Enters Sponsored Project Agreement With Virginia Commonwealth University To Evaluate Aramchol's Effect On Overcoming Drug Resistance In Gastrointestinal Cancers

Author: Benzinga Newsdesk | April 17, 2025 07:33am

• Galmed Pharmaceuticals (NASDAQ:GLMD) enters into a Sponsored Project Agreement with Virginia Commonwealth University (VCU) to evaluate Aramchol's effect on overcoming drug resistance in gastrointestinal (GI) cancers.
  
  
  
   
• Aramchol, a first-in-class SCD1 inhibitor, will be studied in combination with standard therapies for advanced colorectal and liver cancers, aiming to reverse treatment resistance and improve outcomes in these high-mortality cancers.
  
  
  
   
• Collaboration builds on breakthrough findings published in Nature Communications (https://doi.org/10.1038/s41467-023-41852-z) linking lipid metabolism to cancer drug resistance, supporting Aramchol's novel mechanism as a promising, synergistic approach.
• This initiative is part of a strategic expansion of Galmed's pipeline beyond liver disease into oncology, targeting a large market potential with significant unmet need and reinforcing Galmed's focus on cost-effective, innovative therapies.

Posted In: GLMD